HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

Cristina Belizna; Francesca Pregnolato; Sebastien Abad; Jaume Alijotas-Reig; Howard Amital; Zahir Amoura; Laura Andreoli; Emmanuel Andres; Achile Aouba; Sule Apras Bilgen; Laurent Arnaud; Boris Bienvenu; Viktoria Bitsadze; Patrick Blanco; Miri Blank; Maria Orietta Borghi; Antonia Caligaro; Elisabeta Candrea; Valentina Canti; Laurent Chiche; Jean Marie Chretien; Jan Willem Cohen Tervaert; Laura Damian; Teresa Delross; Emmanuelle Dernis; Katrien Devreese; Aleksandra Djokovic; Enrique Esteve-Valverde; Maria Favaro; Celine Fassot; Raquel Ferrer-Oliveras; Alban Godon; Mohamed Hamidou; Milena Hasan; Daniel Henrion; Bernard Imbert; Pierre Yves Jeandel; Pascale Jeannin; Patrick Jego; Noemie Jourde-Chiche; Jamilya Khizroeva; Olivier Lambotte; Cedric Landron; Jose Latino; Estibaliz Lazaro; Karina de Leeuw; Thomas Le Gallou; Levent Kilic; Maarten Limper; Laurent Loufrani; Romain Lubin; Nadine Magy-Bertrand; Guillaume Mahe; Alexander Makatsariya; Thierry Martin; Christian Muchardt; Gyorgy Nagy; Loukman Omarjee; Pieter Van Paasen; Gilles Pernod; Florence Perrinet; Gilberto Pires Rosa; Marc Antoine Pistorius; Amelia Ruffatti; Fatma Said; Patrick Saulnier; Damien Sene; Loic Sentilhes; Ova Shovman; Jean Sibilia; Crina Sinescu; Natasa Stanisavljevic; Ljudmila Stojanovich; Lai Shan Tam; Angela Tincani; Frederic Tollis; Sebastian Udry; Marie Noelle Ungeheuer; Mathilde Versini; Ricard Cervera; Pier Luigi Meroni

doi:10.1016/j.autrev.2018.05.012

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

Cristina Belizna^*, Francesca Pregnolato, Sebastien Abad, Jaume Alijotas-Reig, Howard Amital, Zahir Amoura, Laura Andreoli, Emmanuel Andres, Achile Aouba, Sule Apras Bilgen, Laurent Arnaud, Boris Bienvenu, Viktoria Bitsadze, Patrick Blanco, Miri Blank, Maria Orietta Borghi, Antonia Caligaro, Elisabeta Candrea, Valentina Canti, Laurent ChicheJean Marie Chretien, Jan Willem Cohen Tervaert, Laura Damian, Teresa Delross, Emmanuelle Dernis, Katrien Devreese, Aleksandra Djokovic, Enrique Esteve-Valverde, Maria Favaro, Celine Fassot, Raquel Ferrer-Oliveras, Alban Godon, Mohamed Hamidou, Milena Hasan, Daniel Henrion, Bernard Imbert, Pierre Yves Jeandel, Pascale Jeannin, Patrick Jego, Noemie Jourde-Chiche, Jamilya Khizroeva, Olivier Lambotte, Cedric Landron, Jose Latino, Estibaliz Lazaro, Karina de Leeuw, Thomas Le Gallou, Levent Kilic, Maarten Limper, Laurent Loufrani, Romain Lubin, Nadine Magy-Bertrand, Guillaume Mahe, Alexander Makatsariya, Thierry Martin, Christian Muchardt, Gyorgy Nagy, Loukman Omarjee, Pieter Van Paasen, Gilles Pernod, Florence Perrinet, Gilberto Pires Rosa, Marc Antoine Pistorius, Amelia Ruffatti, Fatma Said, Patrick Saulnier, Damien Sene, Loic Sentilhes, Ova Shovman, Jean Sibilia, Crina Sinescu, Natasa Stanisavljevic, Ljudmila Stojanovich, Lai Shan Tam, Angela Tincani, Frederic Tollis, Sebastian Udry, Marie Noelle Ungeheuer, Mathilde Versini, Ricard Cervera, Pier Luigi Meroni

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.

Original language	English
Pages (from-to)	1153-1168
Number of pages	16
Journal	Autoimmunity Reviews
Volume	17
Issue number	12
DOIs	https://doi.org/10.1016/j.autrev.2018.05.012
Publication status	Published - 1 Dec 2018

Keywords

Antiphospholipid syndrome
Primary antiphospholipid syndrome
Hydroxychloroquine
Secondary prevention
SYSTEMIC-LUPUS-ERYTHEMATOSUS
PREGNANT PATIENTS
RISK-FACTORS
ANTIBODIES
DRUGS
WOMEN
RECOMMENDATIONS
ANTICOAGULANT
COMPLEMENT
MANAGEMENT

Access to Document

10.1016/j.autrev.2018.05.012

Cite this

Belizna, C., Pregnolato, F., Abad, S., Alijotas-Reig, J., Amital, H., Amoura, Z., Andreoli, L., Andres, E., Aouba, A., Bilgen, S. A., Arnaud, L., Bienvenu, B., Bitsadze, V., Blanco, P., Blank, M., Borghi, M. O., Caligaro, A., Candrea, E., Canti, V., ... Meroni, P. L. (2018). HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome. Autoimmunity Reviews, 17(12), 1153-1168. https://doi.org/10.1016/j.autrev.2018.05.012

@article{844e49e26f744d8a9bc870292a1a2e5a,

title = "HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome",

abstract = "The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.",

keywords = "Antiphospholipid syndrome, Primary antiphospholipid syndrome, Hydroxychloroquine, Secondary prevention, SYSTEMIC-LUPUS-ERYTHEMATOSUS, PREGNANT PATIENTS, RISK-FACTORS, ANTIBODIES, DRUGS, WOMEN, RECOMMENDATIONS, ANTICOAGULANT, COMPLEMENT, MANAGEMENT",

author = "Cristina Belizna and Francesca Pregnolato and Sebastien Abad and Jaume Alijotas-Reig and Howard Amital and Zahir Amoura and Laura Andreoli and Emmanuel Andres and Achile Aouba and Bilgen, {Sule Apras} and Laurent Arnaud and Boris Bienvenu and Viktoria Bitsadze and Patrick Blanco and Miri Blank and Borghi, {Maria Orietta} and Antonia Caligaro and Elisabeta Candrea and Valentina Canti and Laurent Chiche and Chretien, {Jean Marie} and Tervaert, {Jan Willem Cohen} and Laura Damian and Teresa Delross and Emmanuelle Dernis and Katrien Devreese and Aleksandra Djokovic and Enrique Esteve-Valverde and Maria Favaro and Celine Fassot and Raquel Ferrer-Oliveras and Alban Godon and Mohamed Hamidou and Milena Hasan and Daniel Henrion and Bernard Imbert and Jeandel, {Pierre Yves} and Pascale Jeannin and Patrick Jego and Noemie Jourde-Chiche and Jamilya Khizroeva and Olivier Lambotte and Cedric Landron and Jose Latino and Estibaliz Lazaro and {de Leeuw}, Karina and {Le Gallou}, Thomas and Levent Kilic and Maarten Limper and Laurent Loufrani and Romain Lubin and Nadine Magy-Bertrand and Guillaume Mahe and Alexander Makatsariya and Thierry Martin and Christian Muchardt and Gyorgy Nagy and Loukman Omarjee and {Van Paasen}, Pieter and Gilles Pernod and Florence Perrinet and Rosa, {Gilberto Pires} and Pistorius, {Marc Antoine} and Amelia Ruffatti and Fatma Said and Patrick Saulnier and Damien Sene and Loic Sentilhes and Ova Shovman and Jean Sibilia and Crina Sinescu and Natasa Stanisavljevic and Ljudmila Stojanovich and Tam, {Lai Shan} and Angela Tincani and Frederic Tollis and Sebastian Udry and Ungeheuer, {Marie Noelle} and Mathilde Versini and Ricard Cervera and Meroni, {Pier Luigi}",

year = "2018",

month = dec,

day = "1",

doi = "10.1016/j.autrev.2018.05.012",

language = "English",

volume = "17",

pages = "1153--1168",

journal = "Autoimmunity Reviews",

issn = "1568-9972",

publisher = "Elsevier Science",

number = "12",

}

Belizna, C, Pregnolato, F, Abad, S, Alijotas-Reig, J, Amital, H, Amoura, Z, Andreoli, L, Andres, E, Aouba, A, Bilgen, SA, Arnaud, L, Bienvenu, B, Bitsadze, V, Blanco, P, Blank, M, Borghi, MO, Caligaro, A, Candrea, E, Canti, V, Chiche, L, Chretien, JM, Tervaert, JWC, Damian, L, Delross, T, Dernis, E, Devreese, K, Djokovic, A, Esteve-Valverde, E, Favaro, M, Fassot, C, Ferrer-Oliveras, R, Godon, A, Hamidou, M, Hasan, M, Henrion, D, Imbert, B, Jeandel, PY, Jeannin, P, Jego, P, Jourde-Chiche, N, Khizroeva, J, Lambotte, O, Landron, C, Latino, J, Lazaro, E, de Leeuw, K, Le Gallou, T, Kilic, L, Limper, M, Loufrani, L, Lubin, R, Magy-Bertrand, N, Mahe, G, Makatsariya, A, Martin, T, Muchardt, C, Nagy, G, Omarjee, L, Van Paasen, P, Pernod, G, Perrinet, F, Rosa, GP, Pistorius, MA, Ruffatti, A, Said, F, Saulnier, P, Sene, D, Sentilhes, L, Shovman, O, Sibilia, J, Sinescu, C, Stanisavljevic, N, Stojanovich, L, Tam, LS, Tincani, A, Tollis, F, Udry, S, Ungeheuer, MN, Versini, M, Cervera, R & Meroni, PL 2018, 'HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome', Autoimmunity Reviews, vol. 17, no. 12, pp. 1153-1168. https://doi.org/10.1016/j.autrev.2018.05.012

TY - JOUR

T1 - HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

AU - Belizna, Cristina

AU - Pregnolato, Francesca

AU - Abad, Sebastien

AU - Alijotas-Reig, Jaume

AU - Amital, Howard

AU - Amoura, Zahir

AU - Andreoli, Laura

AU - Andres, Emmanuel

AU - Aouba, Achile

AU - Bilgen, Sule Apras

AU - Arnaud, Laurent

AU - Bienvenu, Boris

AU - Bitsadze, Viktoria

AU - Blanco, Patrick

AU - Blank, Miri

AU - Borghi, Maria Orietta

AU - Caligaro, Antonia

AU - Candrea, Elisabeta

AU - Canti, Valentina

AU - Chiche, Laurent

AU - Chretien, Jean Marie

AU - Tervaert, Jan Willem Cohen

AU - Damian, Laura

AU - Delross, Teresa

AU - Dernis, Emmanuelle

AU - Devreese, Katrien

AU - Djokovic, Aleksandra

AU - Esteve-Valverde, Enrique

AU - Favaro, Maria

AU - Fassot, Celine

AU - Ferrer-Oliveras, Raquel

AU - Godon, Alban

AU - Hamidou, Mohamed

AU - Hasan, Milena

AU - Henrion, Daniel

AU - Imbert, Bernard

AU - Jeandel, Pierre Yves

AU - Jeannin, Pascale

AU - Jego, Patrick

AU - Jourde-Chiche, Noemie

AU - Khizroeva, Jamilya

AU - Lambotte, Olivier

AU - Landron, Cedric

AU - Latino, Jose

AU - Lazaro, Estibaliz

AU - de Leeuw, Karina

AU - Le Gallou, Thomas

AU - Kilic, Levent

AU - Limper, Maarten

AU - Loufrani, Laurent

AU - Lubin, Romain

AU - Magy-Bertrand, Nadine

AU - Mahe, Guillaume

AU - Makatsariya, Alexander

AU - Martin, Thierry

AU - Muchardt, Christian

AU - Nagy, Gyorgy

AU - Omarjee, Loukman

AU - Van Paasen, Pieter

AU - Pernod, Gilles

AU - Perrinet, Florence

AU - Rosa, Gilberto Pires

AU - Pistorius, Marc Antoine

AU - Ruffatti, Amelia

AU - Said, Fatma

AU - Saulnier, Patrick

AU - Sene, Damien

AU - Sentilhes, Loic

AU - Shovman, Ova

AU - Sibilia, Jean

AU - Sinescu, Crina

AU - Stanisavljevic, Natasa

AU - Stojanovich, Ljudmila

AU - Tam, Lai Shan

AU - Tincani, Angela

AU - Tollis, Frederic

AU - Udry, Sebastian

AU - Ungeheuer, Marie Noelle

AU - Versini, Mathilde

AU - Cervera, Ricard

AU - Meroni, Pier Luigi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.

AB - The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.

KW - Antiphospholipid syndrome

KW - Primary antiphospholipid syndrome

KW - Hydroxychloroquine

KW - Secondary prevention

KW - SYSTEMIC-LUPUS-ERYTHEMATOSUS

KW - PREGNANT PATIENTS

KW - RISK-FACTORS

KW - ANTIBODIES

KW - DRUGS

KW - WOMEN

KW - RECOMMENDATIONS

KW - ANTICOAGULANT

KW - COMPLEMENT

KW - MANAGEMENT

U2 - 10.1016/j.autrev.2018.05.012

DO - 10.1016/j.autrev.2018.05.012

M3 - (Systematic) Review article

C2 - 30316994

SN - 1568-9972

VL - 17

SP - 1153

EP - 1168

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

IS - 12

ER -

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

Abstract

Keywords

Access to Document

Fingerprint

Cite this